ADAM17 and acute lymphoblastic leukemia: This makes an iRhom2 targeting strategy a more specific approach to inhibiting ADAM17-dependent (ligand-independent) Notch signaling, and also opens a potentially translationally relevant new avenue in investigation of T-ALL treatment.